6 results
8-K
EX-99.1
OMIC
Singular Genomics Systems Inc
18 Mar 24
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
4:07pm
launch and advancements of the product pipeline and R&D roadmap.
Net loss for 2023 was $94.8 million, or a loss of $1.30 per common share, compared
8-K
EX-99.1
OMIC
Singular Genomics Systems Inc
7 Nov 22
Singular Genomics Reports Recent Highlights and Third Quarter 2022 Financial Results
4:01pm
our growth, including the G4 launch, product pipeline and R&D roadmap.
Net loss for the third quarter of 2022 was $23.8 million, or $0.33 per common
8-K
EX-99.1
OMIC
Singular Genomics Systems Inc
9 Aug 22
Singular Genomics Reports Recent Highlights and Second Quarter 2022 Financial Results
12:00am
was driven primarily by our product pipeline and R&D roadmap, and scaling headcount and infrastructure to support our growth and prepare
8-K
EX-99.1
OMIC
Singular Genomics Systems Inc
10 May 22
Singular Genomics Systems, Inc. Reports Recent Highlights and First Quarter 2022 Financial Results
4:10pm
and R&D roadmap and the costs associated with being a public company.
Net loss for the first quarter of 2022 was $22.0 million, or $0.31 per common
8-K
EX-99.1
68cs7r8v132jwdaxar
2 Mar 22
Singular Genomics Systems, Inc. Reports Recent Highlights, Fourth Quarter and Full Year 2021 Financial Results
4:05pm
- Prev
- 1
- Next